Dr. Tanya B. Dorff, MD

Dr. Dorff practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Dorff's NPI, 1508879115, was assigned on August 14, 2006. Dr. Dorff graduated from David Geffen School of Medicine at UCLA in 2000. Dr. Dorff holds California license A82669.

Dr. Dorff's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Dorff's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Dorff is also affiliated with Eisenhower Health. The medical group on file is City of Hope. Dmand AI also links Dr. Dorff to 1 more home health agency and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dorff practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Dorff's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dorff is board certified in medical oncology by the American Board of Internal Medicine. Dr. Dorff is licensed in California.

Dmand AI lists chronic anemia, fluid and electrolyte imbalances, lung cancer, multiple myeloma and prostate cancer among the conditions Dr. Dorff treats.

CMS data shows 1,356 Medicare services from Dr. Dorff across 8 procedure codes in 2024, for 517 Medicare patients. Medicare paid $100,857 for them.

CMS counts 517 Medicare patients who saw Dr. Dorff in 2024. The largest group is 65 to 74, with 248 patients. 75% of them have cancer, and 74% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dorff's median patient age at 74, with 4% women.

In 2024, Dr. Dorff wrote 1,464 Medicare Part D claims for 204 patients. 47% of them were for generic drugs. CMS names the drug for 1,242 of them, across 15 drugs with 11 or more claims each, at $6,518,122 in total drug cost. In 2023, CMS named 1,094 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Dorff for performance year 2024, reported as part of a group. Dr. Dorff accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dorff as offering telehealth.

Dmand AI links 100 papers to Dr. Dorff, published from 2009 to 2025. 2024 was the busiest year, with 13. The most frequent topics are Prostatic Neoplasms, Androgen Antagonists and Prostatic Neoplasms, Castration-Resistant. Dr. Dorff has published most often in Clin Genitourin Cancer. Dr. Dorff's most frequent co-authors are Sumanta K. Pal, MD, Abhishek Tripathi, MD and Rana Ramzi McKay, MD.

Dmand AI links Dr. Dorff to 10 clinical trials, 5 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Urinary Bladder Neoplasms. University of Southern California sponsors the most, 6.

CMS Open Payments shows 360 general payments to Dr. Dorff from 37 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 57% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $62,278. It also lists 36 research payments totaling $44,419 from 2020 to 2025.

Dmand AI lists 1 award for Dr. Dorff, most recently Top Doctors:LA Area in 2013.

Dr. Dorff graduated from David Geffen School of Medicine at UCLA in 2000. Dr. Dorff is a member of ASCO.

Dr. Dorff is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.